![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TUBGCP5 |
Gene summary for TUBGCP5 |
![]() |
Gene information | Species | Human | Gene symbol | TUBGCP5 | Gene ID | 114791 |
Gene name | tubulin gamma complex associated protein 5 | |
Gene Alias | GCP5 | |
Cytomap | 15q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q96RT8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114791 | TUBGCP5 | HCC1_Meng | Human | Liver | HCC | 8.55e-19 | 1.74e-02 | 0.0246 |
114791 | TUBGCP5 | HCC1 | Human | Liver | HCC | 6.74e-06 | 4.08e+00 | 0.5336 |
114791 | TUBGCP5 | HCC2 | Human | Liver | HCC | 3.24e-02 | 3.02e+00 | 0.5341 |
114791 | TUBGCP5 | S028 | Human | Liver | HCC | 3.90e-07 | 3.55e-01 | 0.2503 |
114791 | TUBGCP5 | S029 | Human | Liver | HCC | 4.82e-02 | 2.58e-01 | 0.2581 |
114791 | TUBGCP5 | C21 | Human | Oral cavity | OSCC | 9.90e-09 | 3.33e-01 | 0.2678 |
114791 | TUBGCP5 | C30 | Human | Oral cavity | OSCC | 6.73e-07 | 3.14e-01 | 0.3055 |
114791 | TUBGCP5 | C38 | Human | Oral cavity | OSCC | 2.85e-05 | 5.62e-01 | 0.172 |
114791 | TUBGCP5 | C08 | Human | Oral cavity | OSCC | 5.82e-04 | 1.36e-01 | 0.1919 |
114791 | TUBGCP5 | LN22 | Human | Oral cavity | OSCC | 1.32e-04 | 5.05e-01 | 0.1733 |
114791 | TUBGCP5 | SYSMH2 | Human | Oral cavity | OSCC | 2.23e-09 | 2.15e-01 | 0.2326 |
114791 | TUBGCP5 | SYSMH3 | Human | Oral cavity | OSCC | 1.11e-06 | 2.28e-01 | 0.2442 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005125822 | Liver | HCC | protein polymerization | 182/7958 | 297/18723 | 4.17e-11 | 1.58e-09 | 182 |
GO:000705111 | Liver | HCC | spindle organization | 116/7958 | 184/18723 | 1.40e-08 | 3.40e-07 | 116 |
GO:005122511 | Liver | HCC | spindle assembly | 75/7958 | 117/18723 | 1.92e-06 | 2.67e-05 | 75 |
GO:0046785 | Liver | HCC | microtubule polymerization | 51/7958 | 83/18723 | 3.82e-04 | 2.61e-03 | 51 |
GO:0007020 | Liver | HCC | microtubule nucleation | 25/7958 | 35/18723 | 5.05e-04 | 3.29e-03 | 25 |
GO:00311222 | Liver | HCC | cytoplasmic microtubule organization | 35/7958 | 56/18723 | 2.00e-03 | 1.01e-02 | 35 |
GO:0031109 | Liver | HCC | microtubule polymerization or depolymerization | 68/7958 | 122/18723 | 2.14e-03 | 1.08e-02 | 68 |
GO:00070517 | Oral cavity | OSCC | spindle organization | 117/7305 | 184/18723 | 1.16e-11 | 4.17e-10 | 117 |
GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
GO:00512255 | Oral cavity | OSCC | spindle assembly | 73/7305 | 117/18723 | 2.51e-07 | 3.96e-06 | 73 |
GO:00070204 | Oral cavity | OSCC | microtubule nucleation | 28/7305 | 35/18723 | 8.71e-07 | 1.19e-05 | 28 |
GO:00311226 | Oral cavity | OSCC | cytoplasmic microtubule organization | 39/7305 | 56/18723 | 3.29e-06 | 3.93e-05 | 39 |
GO:00467855 | Oral cavity | OSCC | microtubule polymerization | 53/7305 | 83/18723 | 3.96e-06 | 4.65e-05 | 53 |
GO:00311093 | Oral cavity | OSCC | microtubule polymerization or depolymerization | 68/7305 | 122/18723 | 1.29e-04 | 9.21e-04 | 68 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TUBGCP5 | SNV | Missense_Mutation | novel | c.2641N>A | p.His881Asn | p.H881N | Q96RT8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
TUBGCP5 | SNV | Missense_Mutation | novel | c.887N>C | p.Val296Ala | p.V296A | Q96RT8 | protein_coding | tolerated(0.1) | benign(0.04) | TCGA-FP-A4BE-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TUBGCP5 | SNV | Missense_Mutation | rs759151472 | c.2818N>T | p.Arg940Trp | p.R940W | Q96RT8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VQ-A8E3-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TUBGCP5 | SNV | Missense_Mutation | rs758256369 | c.1099N>T | p.Ala367Ser | p.A367S | Q96RT8 | protein_coding | tolerated(0.1) | possibly_damaging(0.644) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |